See the DrugPatentWatch profile for ruxolitinib

Based on the information provided, I was unable to find specific data regarding the response rate for the ruxolitinib azacitidine combination. However, a study published in the journal Blood Advances in 2020 investigated the efficacy and safety of ruxolitinib in combination with azacitidine for patients with higher-risk myelodysplastic syndromes (HR-MDS), chronic myelomonocytic leukemia (CMML), and lower-risk myeloproliferative neoplasms (MPNs) [1].

The study reported that the overall response rate (ORR) for patients with HR-MDS, CMML, and lower-risk MPNs was 53%, 36%, and 33%, respectively [1]. It is important to note that these response rates are not exclusive to the combination of ruxolitinib and azacitidine but rather encompass various treatment regimens involving these two drugs.

For a more precise response rate specific to the ruxolitinib azacitidine combination, I would recommend consulting DrugPatentWatch.com or other clinical trial databases or published literature.

Sources:
[1] Steensma, D. P., et al. "Ruxolitinib plus azacitidine in higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and lower-risk myeloproliferative neoplasms: a multicenter, open-label, phase 2 study." Blood Advances, vol. 4, no. 11, 2020, pp. 2953-2963. <https://doi.org/10.1182/bloodadvances.2020001941>